Physician profile

Ivana Koebel

Tampa, FL

NPI 1144881889

$1,128.28

in general payments reported to CMS, 2019-2025

12 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$122.91

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Biohaven Pharmaceuticals, INC. $338.80 2021
Redhill Biopharma INC. $164.02 2021
Idorsia Pharmaceuticals US INC $122.91 2023 Quviviq
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $115.07 2021
Collegium Pharmaceutical, INC. $109.23 2021
Abbvie INC. $74.81 2022
Allergan, INC. $66.40 2021-2022
Eisai INC. $54.93 2021
Arbor Pharmaceuticals, INC. $28.83 2021
Ibsa Pharma INC. $21.30 2021
Intra-Sana Laboratories $17.78 2021
Amgen INC. $14.20 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ivana Koebel

$1,128.28

in general payments reported 2019-2025

Years
2021-2023
Top company
Biohaven Pharmaceuticals, INC.

https://glasscript.com/doctor/11283404/ivana-koebel

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.